Acute Urinary Retention: A Rare
Presentation in Acute Myeloid Leukemia
Barik S1, Sinha S2
1Dr Sumit Barik, Specialist and designated Associate Professor,
Department of Pathology and Hematology,2Dr Sweta Sinha, Senior
Resident, Department of Transfusion Medicine. Both are affiliated with
ESI Post Graduate Institute of Medical Science and Research, New Delhi.
110015, India
Address for
correspondence: Dr. Sweta Sinha, Email:
sweta20eleven@gmail.com
Abstract
Hyperleukocytosis is defined when the total leukocyte count is more
than 100000/cmm. Leukostasis occurs in hyperleukocytic acute myeloid
leukemia when the numbers of blasts are very high. Leukostasis causes
impaired normal functioning of vascular systems because of crowding of
blasts in its microvasculature or in its vessels supplying the nerves.
Leukostasis causes early deaths in acute myeloid leukemia (AML) due to
involvement of central nervous system and lungs. Acute retention of
urine because of haematological causes is rarely seen. Dysfunction of
bladder because of leukostasis in hyperleukocytic AML is warning.
Cytoreduction therapy in hyperleukocytic AML prevents early deaths.
Key words:
Acute myeloid leukemia, hyperleukocytosis, leukostasis, Urinary
retention.
Introduction
Hematological malignancies like acute leukemias and chronic leukemias
can produce organ or system disorder because of leukostasis. 5
– 30 % cases of acute leukemia present because of
hyperleukocytosis with a total leukocyte count of more than 100000/ cmm
[1]. The microcirculation of the nervous system, lungs, eye
and penis is most sensitive to the effects of leukostasis. Dizziness,
stupor, dyspnea, and priapism may occur [2]. Cerebral haemorrhages and
respiratory failure are grievous complications of hyperleukocytic AML.
The mortality in hyperleukocytic AML is very high and management of
hyperleukocytosis is of utmost importance in saving the patient. The
leukapharesis and chemotherapy is targeted towards faster reduction in
counts and correcting abnormality produced by leukostasis [3]. Urinary
retention because of leukostasis as presentation in acute myeloid
leukemia is rare. Prompt intervention with aim of leukoreduction for
relieving urinary retention prevented other possible complications of
leukostasis in this patient.
Case
Report
A girl of 10 years age was brought by parents in emergency department
with complaints of pain in abdomen and inability to pass urine since
last two days. She also complained of weakness and bodyache. There was
no past history of injury, fever, seizures or unconsciousness. On
examination, bladder was palpable till hypogastrium. Gynaecological
examination ruled out any abnormal finding pertaining to female genital
system. Pallor was evident but no icterus and cyanosis was found. Liver
was not palpable though spleen was palpable just below costal margins.
Any other significant finding could not be elicited in systemic
examination. Ultrasound examination confirmed mild increase in spleen
but any other abnormality was not detected. Urine examination was sent
after evacuating the bladder with catheter. Albumin and sugar were
absent in urine and microscopic examination showed 1 to 2 pus cell per
high power field. Any other abnormality was not found in urine
examination. Hemogram was sent to the department of hematology for cell
counts and type of anemia. Hemoglobin was found to be 5.9 gm %, total
leukocyte count was 1,50, 000 /cmm and platelets were 1,60, 000 /cmm.
Peripheral smear examination showed blasts making 95%, rest were
lymphocytes and neutrophils. Platelets were adequate and no parasite
was seen. A diagnosis of acute myeloid leukemia with hyperleukocytosis
was made.
Figure 1: Hyperleukocytic
Acute myeloid leukemia (M4). (Magnification 100x10x). Myeloblasts and
monoblasts are distinctly seen.
Cytochemistry confirmed acute myelomonocytic leukemia (M4 variety
according to FAB classification). Imaging studies did not show any
compressing lesion or a tumour aggregate (myeloid sarcoma or chloroma)
which could explain bladder dysfunction. A presumptive diagnosis of
Hyperleukocytic AML with Leukostasis was made and patient was sent for
leukoreduction. Leukapharesis was done and the leukocyte counts were
brought down to 80 000/cmm . The function of urinary bladder corrected
and patient was able to pass urine. Definitive induction therapy was
started and other measures like hydration and alkalinisation were done
as a regime for leukoreduction. Urinary retention never occurred again
till her stay in hospital and she was discharged with follow up
instructions.
Discussion
Our patient was diagnosed with hyperleukocytic AML causing bladder
retention. Her leukocyte counts were 1,50 000/cmm and blasts were 95%.
The blasts were myelomonocytic. Hyperleukocytosis is commonly seen in
myelomonocytic AML. The symptoms of hyperleukocytosis are because of
leukostasis in the blood vessels supplying the organ or
system. A very high percentage of circulating blasts with a
very high total count has been associated with leukostasis.
Over-crowding of leukemic blasts in the capillaries of the
microcirculation and effects of soluble cytokines are reason for the
development of leukostasis. Leukemic cell's ability to respond to chemo
tactic cytokines and their expression of specific adhesion molecules
are probably more important in determining whether leukostasis will
develop than the number of circulating blasts [4]. Our patient came
with acute retention of urine. She had hyperleukocytic AML of M4
variety. Leukostasis is more commonly associated with myeloid than
lymphoid leukemias because of the increased size and rigidity of
myeloblast. The arbitrary threshold of leukocyte counts is 1, 00,000
/cmm in acute leukemias, to produce effects of leukostasis. However
chronic leukemias usually require the counts more than 3, 00,000/cmm to
produce effects of leukostasis [2].
Our patient developed dysfunction of urinary bladder because of
leukostasis. Acute limb ischemia, and renal vein thrombosis and aortic
occlusion have all been described with leukostasis and acute
hyperleukocytosis [5]. Uncommonly leukostasis can occur in bladder
neck, testes, penis rarely vulva [2]. Our patient had not shown any
signs of bleeding and her platelet counts were adequate. The imaging
studies ruled out myeloid sarcoma or any other lesion which could
explain bladder dysfunction. Hyperleukocytic AML, absence of bleeding
and no evidence of myeloid sarcoma in imaging studies have led us to
diagnose leukostasis. Leukostatic effect on vascular or nerve supply of
bladder caused dysfunction of bladder. Marbello et al found very high
mortality in hyperleukocytic AML compared to those who had counts less
than 1,00,000/cmm . The major cause had been intracranial haemorrhage
and pulmonary failure [6]. Background knowledge of such
possibility and availability of leukoreduction therapy in the form of
leukapheresis and chemotherapy can prevent early death in AML [7].
Leukapharesis was advised with an aim of correcting bladder dysfunction
and prevention of intracranial and pulmonary effects of leukostasis.
Induction chemotherapy was started and the patient was discharged after
substantial improvement. Cytoreduction by leukaphersesis and
chemotherapy could correct the bladder dysfunction produced by
leukostasis of hyperleukocytic AML.
Conclusion
Acute retention of urine can be a presenting feature in hyperleukocytic
AML because of leukostasis. This condition should be thought when
features like anemia and bone pain is associated with retention of
urine. Cytoreduction therapy should be considered whenever leukocyte
count in AML is more than 1, 00,000/cmm in association with bladder
dysfunction or any other organ dysfunction. This reduces mortality in
AML.
Funding: Nil, Conflict of interest:
Nil
Permission from IRB:
Yes
References
1. Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M.
Leukocytoreduction for acute leukemia. Ther Apher 2002;
6:15–23. [PubMed]
2. Lichtman MA . Classification and clinical manifestations of clonal
myeloid disorders .In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ,
Seligsohn U, Prchal JT, editors. Williams Hematology .8th ed, US: Mc
Graw -Hill and company; 2010: p. 1211-23.
3. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM.
Hyperleukocytosis, leukostasis and leukapheresis: practice management.
Blood Rev. 2012 May; 26(3): 117-22. [PubMed]
4. Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi
A, Mc Carthy LJ. Hyperleukocytic leukemias and leukostasis: a review of
pathophysiology, clinical presentation and management. Leuk Lymphoma.
2000; 39:1-18. [PubMed]
5. Majhail NS, Lichtin A. Acute leukemia with a very high leukocyte
count: Confronting a medical emergency. Cleveland Clinic Journal of
Medicine, 2004; 71(8): 633-7. [PubMed]
6. Marbello L, Ricci F, Nosari AM , Turrini M ,Nador G , Nichelatti M
,Tedeschi A ,Vismara E ,Morra E. Outcome of hyperleukocytic adult acute
myeloid leukaemia: a single-center retrospective study and review of
literature .Leuk Res. 2008 Aug;32(8):1221-7.
7. Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D,
Ottmann OG. Impact of leukapheresis on early death rate in adult acute
myeloid leukemia presenting with hyperleukocytosis. Transfusion 2007
Oct;47(10):1843-50. [PubMed]
How to cite this article?
Barik S, Sinha S. Acute Urinary Retention: A Rare Presentation in Acute
Myeloid Leukemia. Int J Med Res Rev 2014;2(3):267- 269.doi:10.17511/ijmrr.2014.i03.020